ArticleBioMed research international2026
Molecular Identification and Antifungal Susceptibility Patterns of Candida Species in Pediatric Patients at Tabriz Children's Hospital.
Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular Identification and Antifungal Susceptibility Patterns of Candida Species in Pediatric Patients at Tabriz Children's Hospital.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida species are significant opportunistic pathogens, particularly in immunocompromised pediatric populations. With the increasing incidence of invasive candidiasis in neonatal and pediatric intensive care units, accurate species identification and antifungal susceptibility profiling have become critical for effective treatment. This dual-phase study is aimed at: (1) identifying Candida species from clinical samples using conventional and molecular methods (rDNA-ITS sequencing), and (2) evaluating antifungal susceptibility patterns against fluconazole, itraconazole, amphotericin B, and caspofungin. A total of 97 clinical isolates were obtained from pediatric patients for molecular identification, with 67 isolates successfully subcultured and evaluated for antifungal susceptibility testing. Species identification involved culture on selective media, microscopic examination, DNA extraction, and ITS region sequencing. Antifungal susceptibility testing was performed using the broth microdilution method (CLSI M27 standard) with RPMI-1640 medium, incubating at 35°C for 48 h. Minimum inhibitory concentration (MIC) endpoints were determined visually. Molecular identification revealed the following distribution: C. glabrata (50 isolates, 51.5%), C. albicans/dubliniensis complex (34, 35.1%), C. kefyr (5, 5.2%), C. krusei (6, 6.2%), and C. tropicalis (2, 2.1%). Susceptibility testing showed widespread resistance to fluconazole (particularly in C. glabrata, C. albicans, and C. krusei) and amphotericin B; variable resistance to itraconazole (with 100% susceptibility in C. kefyr); and universal susceptibility to caspofungin (97.4%-100% across species). Our findings highlight a concerning epidemiological shift toward nonalbicans species, predominantly C. glabrata, with distinct resistance profiles. While caspofungin remains highly effective, the observed resistance patterns underscore the necessity of routine antifungal susceptibility testing to guide therapy and prevent treatment failure in pediatric candidiasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.